Celltrion Healthcare Co Ltd
KOSDAQ:091990

Watchlist Manager
Celltrion Healthcare Co Ltd Logo
Celltrion Healthcare Co Ltd
KOSDAQ:091990
Watchlist
Price: 75 900 KRW -5.6% Market Closed
Market Cap: 12.5T KRW
Have any thoughts about
Celltrion Healthcare Co Ltd?
Write Note

Celltrion Healthcare Co Ltd
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Celltrion Healthcare Co Ltd
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Celltrion Healthcare Co Ltd
KOSDAQ:091990
Total Liabilities
â‚©2.6T
CAGR 3-Years
20%
CAGR 5-Years
19%
CAGR 10-Years
N/A
C
Chorokbaem Healthcare Co Ltd
KRX:118000
Total Liabilities
â‚©49.4B
CAGR 3-Years
-7%
CAGR 5-Years
3%
CAGR 10-Years
N/A
W
WSI Co Ltd
KOSDAQ:299170
Total Liabilities
â‚©20.3B
CAGR 3-Years
73%
CAGR 5-Years
68%
CAGR 10-Years
N/A
W
Wonik Co Ltd
KOSDAQ:032940
Total Liabilities
â‚©120.4B
CAGR 3-Years
7%
CAGR 5-Years
11%
CAGR 10-Years
7%
H
HLB Life Science Co Ltd
KOSDAQ:067630
Total Liabilities
â‚©179.6B
CAGR 3-Years
80%
CAGR 5-Years
22%
CAGR 10-Years
21%
B
BlueMTec Co Ltd
KOSDAQ:439580
Total Liabilities
â‚©46.8B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Celltrion Healthcare Co Ltd
Glance View

Market Cap
12.2T KRW
Industry
Health Care

Celltrion Healthcare Co Ltd has carved a distinctive niche in the competitive biotechnology landscape by capitalizing on its expertise in biosimilars, which are biopharmaceutical drugs almost identical to original products. The company's origins trace back to a broader vision of democratizing healthcare, striving to make biologic treatments more accessible and affordable worldwide. With its roots in South Korea, Celltrion Healthcare, a subsidiary of Celltrion Inc., has harnessed cutting-edge technology to replicate complex biological drugs. These drugs, usually utilized for chronic conditions such as autoimmune diseases and cancer, are pivotal in offering alternatives to high-cost branded biologics. By focusing on biosimilars, Celltrion addresses both a global healthcare cost crisis and a burgeoning demand for effective therapies as aging populations grow. The business model revolves around developing, manufacturing, and distributing these biosimilars. Celltrion Healthcare primarily benefits from the lower production costs compared to innovator biologics and the subsequent market penetration achieved through competitive pricing. They have established an extensive global distribution network, which enhances their reach. Collaborations with various international partners bolster their presence in strategic markets, allowing comprehensive coverage across multiple continents. Revenue is generated from licensing agreements, direct sales, and strategic partnerships, ensuring a diversified income stream. In parallel, the company's vigorous pipeline of new products promises sustained growth, aimed at expanding their therapeutic portfolio while leveraging their expertise to outpace competitors in this burgeoning field.

Intrinsic Value
64 511.48 KRW
Overvaluation 15%
Intrinsic Value
Price

See Also

What is Celltrion Healthcare Co Ltd's Total Liabilities?
Total Liabilities
2.6T KRW

Based on the financial report for Jun 30, 2023, Celltrion Healthcare Co Ltd's Total Liabilities amounts to 2.6T KRW.

What is Celltrion Healthcare Co Ltd's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
19%

Over the last year, the Total Liabilities growth was 26%. The average annual Total Liabilities growth rates for Celltrion Healthcare Co Ltd have been 20% over the past three years , 19% over the past five years .

Back to Top